

Iron dextran

Cat. No.:	HY-107928		
CAS No.:	9004-66-4		
Target:	Others		
Pathway:	Others		
Storage:	Pure form	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month

Iron dextran

SOLVENT & SOLUBILITY

In Vitro	H ₂ O : ≥ 50 mg/mL * "≥" means soluble, but saturation unknown.
-----------------	---

BIOLOGICAL ACTIVITY

Description	Iron dextran (Fe dextran) can be used in the study of iron-deficiency anemia in animals ^{[1][2]} .								
In Vivo	<p>Iron dextran (FeDex, IP, 4 weeks, 300 μL of 10 mg) treatment does not increase NSR iron but causes iron-trapping in the tetinal vasculature^[1].</p> <p>Four weeks of IP FeDex injection in 2-month-old WT mice leads to iron accumulation in the RPE and rVECs, but did not increase NSR iron or induce photoreceptor degeneration^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="0" style="width: 100%;"> <tr> <td style="width: 30%;">Animal Model:</td> <td>Wild-type (WT) and RS-HepcKO mice^[1].</td> </tr> <tr> <td>Dosage:</td> <td>IP.</td> </tr> <tr> <td>Administration:</td> <td>300 μL of 10 mg daily for 5 days each week for 2 or 4 weeks.</td> </tr> <tr> <td>Result:</td> <td>Markedly elevated iron levels in 2 and 4 weeks of FeDex-injection groups, by 365.4-fold and 405.4-fold, respectively, compared with PBS controls.</td> </tr> </table>	Animal Model:	Wild-type (WT) and RS-HepcKO mice ^[1] .	Dosage:	IP.	Administration:	300 μL of 10 mg daily for 5 days each week for 2 or 4 weeks.	Result:	Markedly elevated iron levels in 2 and 4 weeks of FeDex-injection groups, by 365.4-fold and 405.4-fold, respectively, compared with PBS controls.
Animal Model:	Wild-type (WT) and RS-HepcKO mice ^[1] .								
Dosage:	IP.								
Administration:	300 μL of 10 mg daily for 5 days each week for 2 or 4 weeks.								
Result:	Markedly elevated iron levels in 2 and 4 weeks of FeDex-injection groups, by 365.4-fold and 405.4-fold, respectively, compared with PBS controls.								

REFERENCES

[1]. Wanting Shu, et al. Iron Accumulates in Retinal Vascular Endothelial Cells But Has Minimal Retinal Penetration After IP Iron Dextran Injection in Mice. Invest Ophthalmol Vis Sci. 2019 Oct 1;60(13):4378-4387.

[2]. D. R. ZIMMERMAN, et al. INJECTABLE IRON-DEXTRAN AND SEVERAL ORAL IRON TREATMENTS FOR THE PREVENTION OF IRONDEFICIENCY ANEMIA OF BABY PIGS x. Journal of Animal Science, Volume 18, Issue 4, November 1959, Pages 1409-1415.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA